Test for chromosomal abnormalities such as trisomies in the fetus by assaying fetal cfDNA in the mother's blood. Because the test assays chromosomes it can also detect fetal gender.
NIPT does not carry the increased risk of miscarriage associated with CVS or amniocentesis.
Articles using this Glossary Item
|DNA shed by embryos could offer non-invasive testing||5 July 2018||News|
|Illumina wins NIPT patent case in UK High Court||27 November 2017||News|
|The reflex DNA method is an improvement on current antenatal screening in the UK||27 November 2017||Comment|